Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week.
The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include:
- Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022
- Advancement of our BTX1702 clinical trial for the treatment of rosacea
- Acceleration of our canine BTX1204A dermatitis study